HTSUY (Hisamitsu Pharmaceutical Co) EPS (Basic): $0.44 (TTM As of Nov. 2025)


HTSUY Hisamitsu Pharmaceutical Co Inc HTSUY
84 GF Score
Price $2.94
GF Value $5.41
Valuation Significantly Undervalued
View Full Analysis

What is Hisamitsu Pharmaceutical Co EPS (Basic)?

Hisamitsu Pharmaceutical Co HTSUY 84 EPS (Basic) is $0.44 as of Nov. 2025. GuruFocus rates HTSUY with a GF Score™ of 84/100 and a GF Value™ of $5.41 (Significantly Undervalued).

Hisamitsu Pharmaceutical Co's basic earnings per share (Basic EPS) for the three months ended in Nov. 2025 was $0.11. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Nov. 2025 was $0.44.

Hisamitsu Pharmaceutical Co's EPS (Diluted) for the three months ended in Nov. 2025 was $0.11. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Nov. 2025 was $0.44.

Hisamitsu Pharmaceutical Co's EPS without NRI for the three months ended in Nov. 2025 was $0.11. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Nov. 2025 was 0.45.

During the past 12 months, Hisamitsu Pharmaceutical Co's average EPS without NRIGrowth Rate was 10.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was 22.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 21.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was -0.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Hisamitsu Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 28.60% per year. The lowest was -21.70% per year. And the median was 1.70% per year.

Hisamitsu Pharmaceutical Co  (OTCPK:HTSUY) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Hisamitsu Pharmaceutical Co EPS (Basic) Related Terms

Hisamitsu Pharmaceutical Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co EPS (Basic) Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.28 0.30 0.49 0.43

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.06 0.11 0.11 0.17
HTSUY
84GF Score
Hisamitsu Pharmaceutical Co Inc HTSUY
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Hisamitsu Pharmaceutical Co's Basic EPS for the fiscal year that ended in Feb. 2026 is calculated as

Basic EPS (A: Feb. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(123.532-0)/285.374
=0.43

Hisamitsu Pharmaceutical Co's Basic EPS for the quarter that ended in Nov. 2025 is calculated as

Basic EPS (Q: Nov. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(31.378-0)/286.904
=0.11

EPS (Basic) for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $0.44 mean?
Hisamitsu Pharmaceutical Co (HTSUY) has a EPS (Basic) of $0.44 as of Nov. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hisamitsu Pharmaceutical Co and its competitors.
Is Hisamitsu Pharmaceutical Co's EPS (Basic) too high?
Hisamitsu Pharmaceutical Co's current EPS (Basic) is $0.44. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's EPS (Basic) compare to ZTS?
Hisamitsu Pharmaceutical Co's EPS (Basic) of $0.44 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hisamitsu Pharmaceutical Co and its competitors. Hisamitsu Pharmaceutical Co's current EPS (Basic) is $0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co (HTSUY) is currently considered Significantly Undervalued. The stock's GF Value™ is $5.41, compared to a current price of $2.94 — trading 45.7% below its estimated fair value. The current EPS (Basic) is $0.44. Hisamitsu Pharmaceutical Co's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (HTSUY), the current EPS (Basic) is $0.44 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (HTSUY) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be undervalued. The current stock price of $2.94 is trading 45.7% below its estimated GF Value™ of $5.41. GuruFocus considers Hisamitsu Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for HTSUY:

  • EPS (Basic): $0.44
  • GF Value™: $5.41 vs. price of $2.94 (45.7% below fair value)
  • GF Score™: 84/100

No single metric tells the full story. See the HTSUY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hisamitsu Pharmaceutical Co Business Description

Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
84GF Score

Get the complete analysis for HTSUY

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.94
Price
$5.41
GF Value